| Literature DB >> 31303750 |
Jinse Park1, Si-Eun Kim1, Eun-Joo Kim2, Byung In Lee1, Jee Hyang Jeong3, Hae Ri Na4, Seong Hye Choi5, Do-Young Kang6, Kyung Won Park7.
Abstract
PURPOSE: We assessed the effect of home-based cognitive intervention (HCI) on cognitive function along with brain metabolism by 18F-FDG PET in patients with amnestic MCI (aMCI). PATIENTS AND METHODS: Fifty-seven patients with aMCI from three hospitals were randomized (30 HCI, 27 control). For 12 weeks, subjects received HCI. Thirty-two subjects (15 HCI, 17 control) underwent brain 18-F-FDG-PET imaging at baseline and at 12 and 24 weeks.Entities:
Keywords: brain PET; cognitive training; mild cognitive impairment
Mesh:
Year: 2019 PMID: 31303750 PMCID: PMC6610290 DOI: 10.2147/CIA.S200269
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1The flow diagram of enrollment.
Abbreviations: FU, follow-up; AE, adverse event.
Baseline characteristics and demographics of subjects
| Home-based cognitive intervention group (n=25) | Control group (n=25) | ||
|---|---|---|---|
| Age, years | 70.7 ± 7.5 | 69.7 ± 8.4 | 0.960a |
| Female | 13 (52%) | 15 (60%) | 0.569c |
| Education, years | 10.1 ± 3.3 | 10 ± 3.5 | 0.921b |
| MMSE score | 25.5 ± 2.5 | 25.9 ± 2.8 | 0.374b |
| CDR-SB score | 1.7 ± 0.7 | 1.4 ± 0.9 | 0.099b |
| Modified ADAS-Cog score | 24.6 ± 6.7 | 26.1 ± 7.7 | 0.737a |
| GDS-15 (SGDS-K) | 4.0 ± 4.4 | 3.0 ± 2.3 | 0.382a |
| AChEI medication | 16 (64%) | 11 (44%) | 0.542c |
| Hypertension | 15 (60%) | 17 (68%) | 0.556c |
| Diabetes | 1 (4%) | 5 (20%) | 0.082c |
| Hyperlipidemia | 9 (36%) | 6 (24%) | 0.355c |
| Depression | 1 (4%) | 2 (8%) | 0.552c |
Notes: aStudent’s t-test. bMann–Whitney U-test. cChi-square test.
Abbreviations: AChEI, acetylcholinesterase inhibitors; GDS-15, 15-item version of Geriatric Depression Score.
Changes in efficacy outcomes at 12 and 24 weeks
| Variables | Baseline | Difference (12 weeks) | Difference (24 weeks) | |||||
|---|---|---|---|---|---|---|---|---|
| Intervention group | Control group | Intervention group | Control group (n=25) | Intervention group | Control group | p1) | ||
| Modified ADAS-Cog | 24.6 ± 6.7 | 25.8 ± 7.1 | −1.4 ± 4.7 | −1.2 ± 2.8 | 0.827 | −3.2±4.9 | −1.1±4.2 | 0.070 |
| MMSE | 25.9 ± 2.7 | 26.2 ± 2.6 | 0.1 ± 2.4 | −1.2 ± 1.9 | 0.061 | 0.2±2.4 | −0.1±3.1 | 0.291 |
| CDR-SB | 1.3 ± 0.8 | 1.3 ± 0.8 | −0.1 ± 0.2 | −0.1 ± 0.7 | 1.000 | 0±0.2 | 0.1±0.9 | 0.745 |
| Story memory recall | 7.2 ± 4 | 8.4 ± 2.8 | 1 ± 3.6 | 0.2 ± 3 | 0.375 | 1.1±3.9 | 1±3.4 | 0.923 |
| Story memory delayed recall | 4.1 ± 3.4 | 5.9 ± 3.6 | 1 ± 2.5 | 0.5 ± 4 | 0.643 | 1.8±3.2 | 0.9±4.7 | 0.473 |
| Story memory recognition | 7.2 ± 1.6 | 7.2 ± 1.5 | −0.2 ± 1.7 | 0.4 ± 1.6 | 0.218 | 0.1±1.2 | 0.8±2.7 | 0.256 |
| Story memory total score | 18.5 ± 7.4 | 21.5 ± 6.6 | 1.7 ± 5.9 | 0.2 ± 7.3 | 0.712 | 3.1±6.8 | 2.7±8.5 | 0.912 |
| Digit span (forward) | 6.4 ± 1.4 | 6.1 ± 1.5 | 0 ± 1.3 | −0.6 ± 1.4 | 0.101 | −0.4±1.2 | −0.7±1.7 | 0.570 |
| Digit span (backward) | 3.6 ± 1.2 | 3.6 ± 0.9 | −0.3 ± 1 | −0.1 ± 1.3 | 0.540 | 0.1±1 | −0.2±1.2 | 0.456 |
| Digit span total score | 10 ± 2.4 | 9.7 ± 2.2 | −0.3 ± 1.9 | −0.8 ± 2 | 0.401 | −0.3±1.7 | −1±2.6 | 0.364 |
| Color-word strop | 61.5 ± 30.4 | 68.2 ± 27.5 | 4.4 ± 26.8 | 1.6 ± 25.2 | 0.224 | 2.1±15.8 | −0.4±15.6 | 0.122 |
| COWAT (category) | 11.2 ± 2.7 | 12.5 ± 3.1 | 0.4 ± 1.8 | −0.7 ± 3.5 | 0.143 | 1.3±2.8 | −1.1±3.4 | 0.006 |
| COWAT (letter) | 16.9 ± 6.7 | 20 ± 9 | 2.7 ± 4.5 | −1.8 ± 8.3 | 0.025 | 3.1±5.8 | −0.4±7.6 | 0.055 |
| COWAT total | 28.1 ± 7.9 | 32.4 ± 11 | 3.1 ± 4.6 | −2.5 ± 8.2 | 0.005 | 4.4±6.8 | −1.5±8.2 | 0.004 |
| Digit-symbol test | 39.9 ± 14.6 | 43.9 ± 14.7 | 2.4 ± 6.6 | 4.4 ± 15.7 | 0.413 | 4±7.9 | 5.7±15.2 | 0.322 |
| GDS-15 | 4.0 ± 4.4 | 2.2 ± 2.7 | −1.4 ± 2.4 | 0.6 ± 3.1 | 0.024 | −1.9±3.2 | 0.8±2.2 | 0.004 |
Abbreviations: MMSE, Mini mental status examination; CDR-SB, Clinical dementia rating-sum of box; COWAT, Controlled oral word association test; GDS, Geriatric depression scale.
Figure 2Changes from baseline at 12 weeks and 24 weeks on efficacy outcomes. Cognitive training significantly improved ADAS-Cog score at 24 weeks (A), COWAT total score at 12 and 24 weeks (B) and GDS-15 at 12 and 24 weeks (C). (A) Changes from baseline at 12 weeks and 24 weeks on the Modified ADAS-Cog. (B) COWAT (total) score change from baseline on Intervention group vs Control (C) GDS-15 (SGDS-K) score change from baseline on Intervention group vs Control.
Abbreviation: COWAT, Controlled oral word association test.
The basic demographic features of participants who performed PET CT comparing all participants
| Home-based cognitive intervention group, total (n=25) | Control group, total (n=25) | Home-based cognitive intervention group (PET group) (n=15) | Control group (PET group) (n=17) | ||
|---|---|---|---|---|---|
| Age, years | 70.7 ± 7.5 | 69.7 ± 8.4 | 70.2 ± 8.3 | 71.4 ± 7.7 | 0.926a |
| Female | 13 (52%) | 15 (60%) | 8 (53.3%) | 8 (47.1%) | 0.866b |
| Education, years | 10.1 ± 3.3 | 10 ± 3.5 | 8.7 ± 2.7 | 10.1 ± 3.1 | 0.518 a |
| MMSE score | 25.5 ± 2.5 | 25.9 ± | 26.1 ± 2.3 | 25.9 ± 2.3 | 0.887a |
| CDR-SB score | 1.7 ± 0.7 | 1.4 ± 0.9 | 1.4 ± 0.8 | 1.7 ± 0.8 | 0.102a |
| Modified ADAS-Cog score | 24.6 ± 6.7 | 26.1 ± 7.7 | 24.5 ± 6.9 | 23.3 ± 6.7 | 0.611a |
| GDS-15 (SGDS-K) | 4.0 ± 4.4 | 3.0 ± 2.3 | 3.6 ± 4.4 | 2.9 ± 2.4 | 0.669a |
| AChEI medication | 16 (64%) | 11 (44%) | 7 (46.7%) | 10 (58.8%) | 0.477b |
| Hypertension | 15 (60%) | 17 (68%) | 9 (60.0%) | 11 (64.7%) | 0.932b |
| Diabetes | 1 (4%) | 5 (20%) | 3 (20.0%) | 1 (5.9%) | 0.214b |
| Hyperlipidemia | 9 (36%) | 6 (24%) | 5 (33.3%) | 8 (47.1%) | 0.485b |
| Depression | 1 (4%) | 2 (8%) | 1 (6.7%) | 1 (5.9%) | 0.948 |
Notes: aOne-way ANOVA. bChi-square test
Abbreviations: AChEI, acetylcholinesterase inhibitors; GDS-15, 15-item version of Geriatric Depression.
Figure 3Distribution of SUVr before treatment (A), after treatment (B), and more than 20% increased region after treatment (C) in participant with change (Fig 3-1). Distribution of SUVr before treatment (D), after treatment (E), and no increased region after treatment (F) in participant without change (Fig 3-2).